Inovio Pharmaceuticals
About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Employees: 122
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
372% more call options, than puts
Call options by funds: $373K | Put options by funds: $79K
143% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 14
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
6% more funds holding
Funds holding: 98 [Q3] → 104 (+6) [Q4]
3.98% more ownership
Funds ownership: 33.04% [Q3] → 37.02% (+3.98%) [Q4]
51% less capital invested
Capital invested by funds: $49.6M [Q3] → $24.5M (-$25.1M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
47%
upside
Avg. target
$10.50
415%
upside
High target
$18
782%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 108 / 342 met price target | 47%upside $3 | Neutral Maintained | 13 Jan 2025 |
JMP Securities Roy Buchanan 36% 1-year accuracy 8 / 22 met price target | 782%upside $18 | Market Outperform Reiterated | 10 Jan 2025 |
Financial journalist opinion
Based on 5 articles about INO published over the past 30 days
Neutral
PRNewsWire
3 hours ago
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025.
Neutral
Seeking Alpha
3 weeks ago
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President.
Neutral
Zacks Investment Research
4 weeks ago
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
PRNewsWire
4 weeks ago
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
Neutral
PRNewsWire
4 weeks ago
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference: American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025) Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107" The abstract will be made available on INOVIO's website following the conference.
Neutral
PRNewsWire
1 month ago
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Neutral
PRNewsWire
2 months ago
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings.
Positive
Benzinga
2 months ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Negative
Benzinga
2 months ago
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.
Neutral
PRNewsWire
2 months ago
INOVIO Announces Pricing of $30 Million Public Offering
PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant.
Charts implemented using Lightweight Charts™